37 related articles for article (PubMed ID: 33358840)
1. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H; Zöchbauer-Müller S; Mader RM; Müllauer L; Klikovits T; Bachleitner-Hofmann T; Hoda MA; Prager GW
Thorac Cancer; 2020 Jul; 11(7):1979-1988. PubMed ID: 32438515
[TBL] [Abstract][Full Text] [Related]
3. Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Tang LK; Li ZK; Xiang YL; Ma DY; Du GB
Medicine (Baltimore); 2023 Jul; 102(30):e34349. PubMed ID: 37505161
[TBL] [Abstract][Full Text] [Related]
4. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab.
Fujiwara S; Kano Y; Maejima Y; Fujioka T; Tamura K; Kirimura S; Miyake S; Okamoto R
Intern Med; 2024 Feb; 63(4):513-519. PubMed ID: 37380459
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal Mesothelioma Chronicles.
Fatima A; MacSweeney F; Riaz T; Heneghan J
Ir Med J; 2024 May; 117(5):964. PubMed ID: 38801147
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
Bansal VV; Mitchell O; Drazer MW; Kindler HL; Turaga KK
Ann Surg Oncol; 2024 Jun; 31(6):3785-3786. PubMed ID: 38502295
[No Abstract] [Full Text] [Related]
7. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
9. Maintaining 'standards' for biosimilar monoclonal antibodies.
Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
[No Abstract] [Full Text] [Related]
10. Vocal Fold Motion Impairment Following Chemotherapy Administration: Case Reports and Review of the Literature.
Talmor G; Nguyen B; Geller MT; Hsu J; Kaye R; Caloway C
Ann Otol Rhinol Laryngol; 2021 Apr; 130(4):405-415. PubMed ID: 33501843
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review.
Tsujii N; Usami M; Naya N; Tsuji T; Mishima H; Horie J; Fujiwara M; Iida J
Neurol Ther; 2021 Dec; 10(2):499-522. PubMed ID: 34089145
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites.
Wang ST; Chiu CF; Bai HJ; Bai LY
Eur J Cancer; 2021 May; 148():48-50. PubMed ID: 33735808
[No Abstract] [Full Text] [Related]
15. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
16. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
17. Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.
Baldi A; De Luca A; Maiorano P; D'Angelo C; Giordano A
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155978
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
